Monoprost (Latanoprost)

Latanoprost activates prostaglandin F (FP) receptors in the eye, increasing the uveoscleral outflow of aqueous humor. This enhanced drainage reduces intra‑ocular pressure, which is the primary therapeutic goal in glaucoma and ocular hypertension.

The dosing regimen for Monoprost is determined by the prescribing ophthalmologist. Typically, a single drop is instilled in the affected eye(s) once daily in the evening, but the exact schedule should follow the clinician’s instructions.

Safety data for latanoprost in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by the treating physician.

To request Monoprost, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monoprost (latanoprost) is a prostaglandin analog, generally offering once‑daily dosing and a favorable efficacy profile compared with beta‑blocker or carbonic anhydrase inhibitor drops. Its side‑effect profile, such as iris darkening, differs from other classes, making individual patient factors important in selection.

Monoprost should be stored at room temperature, below 25 °C, in the original packaging. Protect the bottle from direct sunlight and moisture to maintain stability. Do not freeze the product.

Monoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. Patients should wash their hands before use, avoid touching the tip to the eye or any surface, and close the eye gently after instillation.

Serious risks, though rare, include severe allergic reactions, uveitis, macular edema, and sudden loss of vision. Any sudden eye pain, redness, or visual changes should prompt immediate medical evaluation.

Monoprost is contraindicated in patients with known hypersensitivity to latanoprost or any component of the formulation, and it should be avoided in eyes with active inflammation or infection. Clinicians should also exercise caution in patients with a history of herpetic eye disease.